Daniel Silver, MD

Daniel P. Silver, MD, PhD

Contact Dr. Silver

233 S. 10th Street
Philadelphia, PA 19107

(215) 955-2054
(215) 955-5391 fax

Most Recent Peer-reviewed Publications

  1. MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy
  2. BRCA1 pathway function in basal-like breast cancer cells
  3. Mechanisms of BRCA1 tumor suppression
  4. Mutational processes molding the genomes of 21 breast cancers
  5. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents
  6. Chek2 DNA damage response pathway and inherited breast cancer risk
  7. Poly ADP-ribose polymerase inhibitors: Science and current clinical development
  8. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
  9. Poly(ADP-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer
  10. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer
  11. Complex landscapes of somatic rearrangement in human breast cancer genomes
  12. Estrogen receptor-negative breast cancer: New insights into subclassification and targeting
  13. Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells
  14. Synthetic lethality - A new direction in cancer-drug development
  15. Cancer: Crossing over to drug resistance
  16. Further Evidence for BRCA1 Communication with the Inactive X Chromosome
  17. Abnormalities of the inactive X chromosome are a common feature of brca1 mutant and sporadic basal-like breast cancer
  18. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects
  19. Association of BRCA1 with the inactive X chromosome and XIST RNA
  20. HIN-1 and the nosology of breast cancer